Download PDF

1. Company Snapshot

1.a. Company Description

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States.The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock.


The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter.It has a strategic collaboration with Tyme Technologies, Inc.for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas.


Eagle Pharmaceuticals, Inc.was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Show Full description

1.b. Last Insights on EGRX

Eagle Pharmaceuticals' recent performance was driven by a series of strategic initiatives. The company's Board of Directors approved an amendment to its limited duration stockholder rights plan, increasing the initial purchase price of each preferred share purchase right from $10.00 to $20.00. This move demonstrates the company's commitment to protecting shareholder value. Additionally, the company's focus on strategic growth and expansion is evident in its recent efforts.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Price Passes Below 200 Day Moving Average – What’s Next?

Nov -22

Source: defenseworld.net

Card image cap

Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements

Oct -15

Source: globenewswire.com

Card image cap

Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements

Oct -15

Source: globenewswire.com

Card image cap

Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements

Oct -06

Source: globenewswire.com

Card image cap

Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years

Sep -17

Source: globenewswire.com

Card image cap

Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors

Aug -28

Source: globenewswire.com

Card image cap

Eagle Pharmaceuticals Announces 2025 Annual Meeting Date

Aug -18

Source: globenewswire.com

Card image cap

Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

Mar -21

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.10%)

6. Segments

Injectable Drugs

Expected Growth: 8.1%

Growing demand for sterile, pre-filled, and ready-to-administer medications in oncology and critical care, driven by increasing incidence of cancer and critical illnesses, coupled with the need for convenient and efficient treatment options, is expected to drive the growth of Eagle Pharmaceuticals' injectable drugs.

7. Detailed Products

Benznidazole

Benznidazole is an anti-parasitic medication used to treat Chagas disease.

Ryanodex

Ryanodex is a medication used to treat malignant hyperthermia, a life-threatening medical emergency.

Zylera

Zylera is an antibiotic used to treat certain bacterial infections, including community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

Albenza

Albenza is an anthelmintic medication used to treat parasitic infections such as hookworm and tapeworm infections.

Targadox

Targadox is an antibiotic used to treat bacterial infections, including community-acquired pneumonia and acute bacterial skin and skin structure infections.

8. Eagle Pharmaceuticals, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Eagle Pharmaceuticals, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and generic drugs in the market.

Bargaining Power Of Customers

The bargaining power of customers is low due to the specialized nature of Eagle Pharmaceuticals, Inc.'s products and the lack of alternative options for patients.

Bargaining Power Of Suppliers

The bargaining power of suppliers is moderate due to the presence of multiple suppliers for raw materials and the company's dependence on a few key suppliers.

Threat Of New Entrants

The threat of new entrants is high due to the growing demand for pharmaceuticals and the increasing trend of outsourcing manufacturing to contract manufacturers.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of established players in the market and the increasing competition for market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 0.00%
Debt Cost 6.26%
Equity Weight 100.00%
Equity Cost 6.26%
WACC 6.26%
Leverage 0.00%

11. Quality Control: Eagle Pharmaceuticals, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Eagle Pharma

A-Score: 5.0/10

Value: 10.0

Growth: 1.8

Quality: 8.3

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Organogenesis Holdings

A-Score: 4.6/10

Value: 8.4

Growth: 3.9

Quality: 5.5

Yield: 0.0

Momentum: 8.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Cyclo Therapeutics

A-Score: 3.8/10

Value: 8.0

Growth: 3.4

Quality: 5.0

Yield: 0.0

Momentum: 5.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Cumberland Pharmaceuticals

A-Score: 3.3/10

Value: 6.9

Growth: 2.3

Quality: 5.2

Yield: 0.0

Momentum: 5.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
TherapeuticsMD

A-Score: 3.2/10

Value: 7.3

Growth: 4.8

Quality: 5.0

Yield: 0.0

Momentum: 0.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Rockwell Medical

A-Score: 2.6/10

Value: 6.4

Growth: 4.2

Quality: 3.4

Yield: 0.0

Momentum: 0.5

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.7$

Current Price

0.7$

Potential

-0.00%

Expected Cash-Flows